SPY311.36-0.82 -0.26%
DIA263.33+0.16 0.06%
IXIC9,615.81-67.10 -0.69%
Alkermes to Take Part in 41st Annual Goldman Sachs Global Healthcare Conference
PR Newswire · 9h ago
Alkermes (ALKS) Up 21.6% Since Last Earnings Report: Can It Continue?
Zacks · 6d ago
Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual Meeting
PR Newswire · 05/27 12:00
Journal of Clinical Psychiatry Publishes Data from Alkermes' ALPINE Study in Patients With Schizophrenia
PR Newswire · 05/20 12:00
Alkermes Presents New Data From Schizophrenia Portfolio at Virtual 2020 Congress of the Schizophrenia International Research Society
PR Newswire · 05/14 12:00
Alkermes To Present New Data From Schizophrenia Portfolio At SIRS Meeting
Alkermes plc (NASDAQ:ALKS) today announced the presentation of new data from its schizophrenia portfolio as part of the virtual 2020 Congress of the Schizophrenia International Research Society (SIRS). New e-posters
Benzinga · 05/14 11:15
Edited Transcript of ALKS earnings conference call or presentation 29-Apr-20 12:00pm GMT
Thomson Reuters StreetEvents · 05/14 02:39
Alkermes Announces Upcoming Presentation at the Bank of America Securities Virtual Health Care Conference
PR Newswire · 05/06 21:00
Analysts Have Lowered Expectations For Alkermes plc (NASDAQ:ALKS) After Its Latest Results
Simply Wall St. · 05/01 14:45
Alkermes' (ALKS) Q1 Earnings Increase Y/Y, Revenues Beat
Zacks · 04/30 16:12
HC Wainwright & Co. Reiterates Neutral on Alkermes, Lowers Price Target to $23
HC Wainwright & Co. reiterates Alkermes (NASDAQ:ALKS) with a Neutral and lowers the price target from $25 to $23.
Benzinga · 04/30 11:23
Alkermes PLC (ALKS) Q1 2020 Earnings Call Transcript
Motley Fool · 04/29 20:00
Alkermes Q1 EPS $0.010 Beats $(0.060) Estimate, Sales $246.220M Beat $228.230M Estimate
Alkermes (NASDAQ:ALKS) reported quarterly earnings of $0.010 per share which beat the analyst consensus estimate of $(0.060) by 116.67 percent. This is a 105.88 percent increase over losses of $(0.170) per share from the
Benzinga · 04/29 17:31
Alkermes plc's (ALKS) CEO Richard Pops on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 04/29 16:53
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.)
Benzinga · 04/29 12:40
Alkermes: Q1 Earnings Insights
Shares of Alkermes (NASDAQ:ALKS) rose 0.6% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 105.88% year over year to $0.01, which beat the estimate of ($0.06).
Benzinga · 04/29 11:47
Alkermes Q1 2020 Earnings Preview
Alkermes (NASDAQ:ALKS) is scheduled to announce Q1 earnings results on Wednesday, April 29th, before market open. The consensus EPS Estimate is -$0.05 (+70
seekingalpha · 04/29 02:30
What's in Store for Innoviva (INVA) This Earnings Season?
Zacks · 04/28 16:58
ANIK vs. ALKS: Which Stock Should Value Investors Buy Now?
Zacks · 04/28 16:40
The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight
The week ended April 24 turned out to be an up-and-down one for biotech stocks, as the sector swayed along with the broader market.
Benzinga · 04/26 20:37